Mayan Katz

• Johnson & Johnson and its subsidiaries in connection with:
  • the sale of one of its drug product lines to Baxter International
  • the strategic alliance with Apple to deploy the Apple Watch to detect atrial fibrillation and the launch of the Heartline™ Study
  • the transfer of collaboration rights and assets to Pharma Mar
  • the $155 million sale of injectable anesthesia and pain management products to Piramal Enterprises’ critical care division*
  • the spin-out of Tusker Medical Inc. to Apple Tree Partners*
• EQRx in connection with:
  • its $1.8 billion proposed business combination with CM Life Sciences III
• Clarus Therapeutics in connection with:
  • its business combination with Blue Water Acquisition Corp.
  • its senior debt financing of up $75 million
  • its convertible note financings
• bluebird bio in its strategic alliance with National Resilience and the related acquisition by Resilience of bluebird’s manufacturing facility in North Carolina for $110 million
• Centessa Pharmaceuticals in its $250 million financing round in parallel with the simultaneous acquisition by Centessa of 10 private biotech companies across four jurisdictions
• Cadent Therapeutics in its acquisition by Novartis for up to $770 million, including an upfront payment of $210 million and up to $560 million in milestone payments
• Cerevel Therapeutics in its business combination with ARYA Sciences Acquisition Corp. II
• AMAG Pharmaceuticals in connection with:
  • the divestment of its women’s health assets
  • the sale of its rights to Intrarosa® to Millicent Pharma for up to $125 million
• Ikena Oncology in its acquisition of Amplify Medicines
• Shields Health Solutions in its equity investments from Welsh, Carson, Anderson & Stowe and Walgreen Co.
• Zealand Pharma in its $205 million royalty and milestone monetization from Royalty Pharma
• Enterome in its global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical
• E-commerce company Lazada Group on the $1 billion sale of a controlling stake in the company to Alibaba, which was named “M&A Deal of the Year: Southeast Asia” at The Asian Lawyer’s 2017 Asia Legal Awards.*
• A private equity firm in its investment in a leading Mid-Atlantic eye care platform.*
• A wholly-owned subsidiary of an S&P 500 pharmaceutical company in its equity and debt financing of a private life sciences company*
• An affiliate of a leading biopharmaceutical company in an asset spin off and a collaboration and license agreement with a company co-founded by a US-based investment firm*
• A multinational medical device company in its $51 million acquisition of assets and a subsequent joint venture*
• A leading 3D printing company on a series of substantial acquisitions for $695 million*
• A multinational technology corporation on a series of cross-border acquisitions*

• Nested Therapeutics launch and its $125 million in financing, including its initial financing by Versant Ventures and its $90 million Series A financing
• Cathay Health, Polaris Partners, and Newpath Partner in their investments as lead investors in the $60 million Series A financing of Kojin Therapeutics
• Johnson & Johnson and its subsidiaries in connection with the investment as lead investor of the $1.3 billion Series B financing of Grail, Inc., which was named LMG Life Sciences 2017 “Impact Deal of the Year”*
• EQRx in connection with:
  • its $500 million Series B financing
  • its $200 million Series A financing
• Stablix Therapeutics in its $63 million Series A financing
• Orbia Ventures in connection with:
  • its investment as lead investor in the $21 million Series B financing of Battery Resources
  • its investment in Silvec Biologics
  • its $3 investment in SeeTree
• Augmedics in its $36 million Series C financing
• 5AM Ventures in its investment as lead investor in the $78 million Series A financing and $120 million Series B financing of Artiva Biotherapeutics
• Perceptive Advisors in its investment as lead investor in the $85 million Series B financing of Athira Pharma
• A healthcare company in its reorganization and series seed financing*
• A private Israeli company in its $15.5 million Series B financing from several venture capital funds*
• Mr. Katz also represents leading life sciences venture capital and investment firms in connection with their portfolio investments and related matters.

• Vascular Biogenics in its $28.3 million public follow-on offering on The Nasdaq Global Market
• The underwriters in Itamar Medical’s $40 million public offering on The Nasdaq Capital Market
• The underwriters in BioLineRx’s $15 million follow-on offering on The Nasdaq Capital Market
• Advaxis in its $20 million public follow-on offering on The Nasdaq Capital Market
• Zealand Pharma in its upsized $90 million IPO on The Nasdaq Global Select Market*
• A leading 3D printing company in its $481 million follow-on public offering on The Nasdaq Global Select Market*
• A leading 3D printing company in its merger and subsequent registration statement on The Nasdaq Global Select Market*

Mr. Katz is an active participant in Goodwin’s Neighborhood Business Initiative and a member of its Steering Committee in the New York Office. He has participated and counseled on multiple pro bono legal clinics, and regularly advises non-profit organizations in connection with corporate governance and transactional matters, including on mergers of Connecticut-based organizations.